CASE REPORT
A successful management with electroconvulsive therapy of neuroleptic malignant syndrome due to amisulpride
 
More details
Hide details
1
Department of Child and Adolescent Psychiatry, Gaziantep Child State Hospital, Gaziantep, Turkey
 
2
Department of Psychiatry, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
 
3
Erenköy Training and Research Hospital for Psychiatric and Neurological Diseases, Department of Psychiatry, İstanbul, Turkey
 
4
Department of Psychiatry, Hitit University, Faculty of Medicine, Çorum, Turkey
 
 
Submission date: 2018-01-14
 
 
Acceptance date: 2018-01-19
 
 
Online publication date: 2018-02-14
 
 
Publication date: 2018-02-13
 
 
Electron J Gen Med 2018;15(3):em14
 
KEYWORDS
TOPICS
ABSTRACT
Neuroleptic malignant syndrome is a severe complication that mainly occurs based on neuroleptic drug treatment and characterized with some autonomic symptoms, altered mental state, hyperthermia and muscle rigidity. Amisulpride is a unique atypical antipsychotic that selectively blocks D2 and D3 receptors presynaptically in the frontal cortex and atypical antipsychotics are rarely caused neuroleptic malignant syndrome(NMS).This study examine a 20-years old male with the diagnosis of acute psychotic disorder occurred amisulpride-induced NMS and successfully treated with Electroconvulsive Therapy (ECT). We decided to present that case because of the fact that there is only limited number of amisulpride-induced NMS cases reported in the literature.
 
REFERENCES (25)
1.
Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. The American journal of psychiatry. 1998;155(8):1113-6. PubMed PMID: 9699705. Epub 1998/08/12. https://doi.org/10.1176/ajp.15....
 
2.
Levenson JL. Neuroleptic malignant syndrome. The American journal of psychiatry. 1985;142(10):1137-45. PubMed PMID: 2863986. Epub 1985/10/01. https://doi.org/10.1176/ajp.14....
 
3.
Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. The American journal of psychiatry. 2002;159(1):149-50. PubMed PMID: 11772710. Epub 2002/01/05. https://doi.org/10.1176/appi.a....
 
4.
Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28(1):89-98. PubMed PMID: 14687862. Epub 2003/12/23. https://doi.org/10.1016/j.pnpb....
 
5.
Khaldi S, Kornreich C, Choubani Z, Gourevitch R. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]. L'Encephale. 2008;34(6):618-24. PubMed PMID: 19081460. Epub 2008/12/17. Antipsychotiques atypiques et syndrome malin des neuroleptiques: breve revue de la litterature. https://doi.org/10.1016/j.ence....
 
6.
Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. The Journal of pharmacology and experimental therapeutics. 1997;280(1):83-97. PubMed PMID: 8996185. Epub 1997/01/01.
 
7.
Shoirah H, Hamoda HM. Electroconvulsive therapy in children and adolescents. Expert review of neurotherapeutics. 2011;11(1):127-37. PubMed PMID: 21158560. Epub 2010/12/17. https://doi.org/10.1586/ern.10....
 
8.
Rey JM, Walter G. Half a century of ECT use in young people. The American journal of psychiatry. 1997;154(5):595-602. PubMed PMID: 9137112. Epub 1997/05/01. https://doi.org/10.1176/ajp.15....
 
9.
Guy W. Early clinical drug evaluation unit (ECDEU) asssment manual psychopharmology. Revised. Rockville, National Institude of Mental Health US.1976;76:217-22.
 
10.
Kostakoğlu E, Batur S, Tiryaki A, Göğüş A. Pozitif ve Negatif Sendrom Ölçeğinin (PANSS) Türkçe uyarlamasının Geçerlilik ve Güvenilirliği. Türk Psikoloji Dergisi. 1999;14:23-32.
 
11.
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Current neuropharmacology. 2015;13(3):395-406. PubMed PMID: 26411967. PMCID: 4812801. Epub 2015/09/29. https://doi.org/10.2174/157015....
 
12.
de Oliveira IR, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. Journal of clinical pharmacy and therapeutics. 1996;21(5):349-58. PubMed PMID: 9119918. Epub 1996/10/01. https://doi.org/10.1111/j.1365....
 
13.
Mandal N, Singh OP, Sen S. Extrapyramidal side effects with low doses of amisulpride. Indian journal of psychiatry. 2014;56(2):197-9. PubMed PMID: 24891713. PMCID: 4040073. Epub 2014/06/04. https://doi.org/10.4103/0019-5....
 
14.
Tu MC, Hsiao CC. Amisulpride and neuroleptic malignant syndrome. Chang Gung medical journal. 2011;34(5):536-40. PubMed PMID: 22035899. Epub 2011/11/01.
 
15.
Musshoff F, Doberentz E, Madea B. Lethal neuroleptic malignant syndrome due to amisulpride. Forensic science, medicine, and pathology. 2013;9(2):218-20. PubMed PMID: 23504701. Epub 2013/03/19. https://doi.org/10.1007/s12024....
 
16.
Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs in R&D. 2015;15(1):45-62. PubMed PMID: 25578944. PMCID: 4359181. Epub 2015/01/13. https://doi.org/10.1007/s40268....
 
17.
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. British journal of anaesthesia. 2000;85(1):129-35. PubMed PMID: 10928001. Epub 2000/08/06. https://doi.org/10.1093/bja/85....
 
18.
Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. Journal of neurology, neurosurgery, and psychiatry. 1995;58(3):271-3. PubMed PMID: 7897404. PMCID: 1073359. Epub 1995/03/01. https://doi.org/10.1136/jnnp.5....
 
19.
Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y. Malignant neuroleptic syndrome--its present status in Japan and clinical problems. Folia psychiatrica et neurologica japonica. 1977;31(4):559-76. PubMed PMID: 608659. Epub 1977/01/01. https://doi.org/10.1111/j.1440....
 
20.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981;30(2):239-45. PubMed PMID: 7249508. Epub 1981/08/01. https://doi.org/10.1038/clpt.1....
 
21.
Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. The Australian and New Zealand journal of psychiatry. 1999;33(5):650-9. PubMed PMID: 10544988. Epub 1999/11/02. https://doi.org/10.1080/j.1440....
 
22.
Casey DA. Electroconvulsive Therapy in the Neuroleptic Malignant Syndrome. Convulsive therapy. 1987;3(4):278-83. PubMed PMID: 11940929. Epub 1987/01/01.
 
23.
Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta psychiatrica Scandinavica. 1986;73(4):337-47. PubMed PMID: 2873715. Epub 1986/04/01. https://doi.org/10.1111/j.1600....
 
24.
Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists. 2012;24(2):155-62. PubMed PMID: 22563571. Epub 2012/05/09.
 
25.
Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacology bulletin. 1991;27(3):381-4. PubMed PMID: 1685592. Epub 1991/01/01.
 
eISSN:2516-3507
Journals System - logo
Scroll to top